Mounjaro vs Ozempic: Weight Loss, Diabetes and Costs

Mounjaro and Ozempic can both affect weight, but neither brand is FDA-approved for weight management. Mounjaro contains tirzepatide; Ozempic contains semaglutide. SURPASS-2 directly compared the molecules in adults with type 2 diabetes, using semaglutide 1 mg rather than Ozempic’s 2 mg maximum. The often-quoted 20.2% versus 13.7% weight-loss result comes from SURMOUNT-5, a different trial of weight-management doses in adults without diabetes. If your main goal is weight loss, discuss the relevant approved brands, Zepbound and Wegovy. Heart and kidney conditions, tolerability and coverage can change the decision.

The decision matrix, find your situation:

• •Type 2 diabetes and weight concerns: Ask about the SURPASS-2 results and their limits. Compare the prescribed product and the dose studied before comparing programs.
• •Type 2 diabetes with heart or kidney disease: Both brands now have defined cardiovascular indications; Ozempic also has a kidney-related indication. Mounjaro’s label changed in August 2026. Ask which evidence fits your diagnosis.
• •Weight management without diabetes: Compare the relevant Zepbound and Wegovy indications, rather than assuming an Ozempic or Mounjaro result transfers unchanged.
• •If insurance denies you and you're paying cash → compare Gala's compounded tirzepatide microdose from $149/mo on its current three-month offer, Embody from $79/mo on a selected plan, and every cash path on /cheapest. TrimRx's landing advertises $179, but its terms list semaglutide at $199 first order/$299 follow-up and GLP-1 + GIP at $349/$399; do not treat $179 as an all-in total.
• •Prefer tablets: Use the oral GLP-1 guide to distinguish approved oral products from Wellorithm’s compounded oral dissolving tirzepatide. The latter is not an approved oral form of Mounjaro.
• •Not sure which fits? Take the 2-minute match quiz or estimate your real out-of-pocket on the cost calculator.

This guide separates glucose-control evidence, weight-management trials and the current Mounjaro and Ozempic labels. For the broader ingredient and formulation comparison, read semaglutide vs tirzepatide.

What Are Mounjaro and Ozempic?

Mounjaro is Eli Lilly’s tirzepatide brand. Its current label covers glucose control in adults and children aged 10 years and older with type 2 diabetes, plus cardiovascular risk reduction in adults with type 2 diabetes at high cardiovascular risk. It is a weekly injection, with an adult maximum of 15 mg. A clinician determines the dose.

Ozempic is Novo Nordisk’s semaglutide brand. Its current label covers glucose control in adults with type 2 diabetes, cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease, and specified kidney-related risks in adults with type 2 diabetes and chronic kidney disease. It is a weekly injection, with a maximum dose of 2 mg.

Mounjaro and Zepbound contain tirzepatide; Ozempic and Wegovy contain semaglutide. Shared ingredients do not erase differences in indication, dosing, formulation or trial population. Use the study that matches the question you are trying to answer.

How Do Mounjaro and Ozempic Work?

The receptor targets differ, but clinical trials, rather than the number of receptors alone, tell us about treatment outcomes.

Ozempic (semaglutide) is a single-agonist, it mimics one gut hormone, GLP-1 (glucagon-like peptide-1). GLP-1 lowers blood sugar by stimulating insulin release when glucose is high, slows how fast your stomach empties, and acts on appetite centers in the brain to reduce hunger.

Mounjaro (tirzepatide) is a dual agonist, it mimics GLP-1 and a second gut hormone, GIP (glucose-dependent insulinotropic polypeptide), in a single molecule. The theory, supported by the trial data, is that engaging both incretin pathways improves glucose handling and appetite suppression more than GLP-1 alone. Tirzepatide is the first dual GIP/GLP-1 receptor agonist the FDA approved.

Which Produces More Weight Loss: Mounjaro or Ozempic?

The answer depends on the patient group and doses. SURMOUNT-5, published in 2025, is the direct obesity comparison commonly quoted online. It is not a trial of the maximum approved Ozempic dose in people with diabetes.

SURMOUNT-5 randomized 751 adults with obesity but without type 2 diabetes to the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or semaglutide (1.7 mg or 2.4 mg) for 72 weeks. The result: tirzepatide produced −20.2% mean body-weight reduction versus −13.7% for semaglutide, a 6.5 percentage-point advantage that was statistically significant (p<0.001). In absolute terms, that was roughly 22.8 kg of weight lost on tirzepatide versus 15.0 kg on semaglutide.

Participants on tirzepatide were also more likely to hit the bigger milestones, losing at least 10%, 15%, 20%, and 25% of their body weight, and saw a larger reduction in waist circumference (−18.4 cm vs −13.0 cm).

What Did the Diabetes Trial Actually Compare?

SURPASS-2, published in 2021, randomized 1,879 adults with type 2 diabetes to tirzepatide 5, 10 or 15 mg or semaglutide 1 mg for 40 weeks. It is the more relevant head-to-head for the diabetes question.

The published primary analysis reported average HbA1c reductions of 2.01, 2.24 and 2.30 percentage points with tirzepatide 5, 10 and 15 mg, respectively, versus 1.86 percentage points with semaglutide 1 mg. These are changes in HbA1c, not percentages of body weight lost.

How Do Their Heart and Kidney Indications Compare?

Both brands now have cardiovascular indications for defined groups with type 2 diabetes. Mounjaro’s August 2026 label includes adults at high cardiovascular risk. Ozempic’s label specifies adults with established cardiovascular disease and also includes a kidney-related indication in adults with type 2 diabetes and chronic kidney disease.

SURPASS-CVOT, described in Mounjaro’s current label, compared tirzepatide with dulaglutide. It was not a cardiovascular comparison with Ozempic. This result cannot establish Mounjaro’s superiority over semaglutide for preventing heart attacks or strokes.

SELECT is a different question: it studied semaglutide 2.4 mg in adults with established cardiovascular disease and overweight or obesity, without diabetes. It underpins Wegovy’s cardiovascular evidence; it should not be described as an Ozempic trial in people with diabetes.

Are Mounjaro and Ozempic Approved for Weight Loss?

A clinician may consider off-label treatment when appropriate, but an off-label prescription does not guarantee insurance payment. The exact product, diagnosis and plan criteria matter.

• •Coverage is not automatic. For a weight-management indication, investigate the relevant Wegovy or Zepbound benefit with your plan. For type 2 diabetes, check the plan’s criteria for Mounjaro or Ozempic.
• •Dose schedules differ. Ozempic has a 2 mg maximum; the current Wegovy label includes additional formulations and doses. Do not treat a brand switch or the larger milligram number as a dose conversion.

If weight loss is your goal and you don't have diabetes, the cleaner path is the on-label twin: Zepbound vs Mounjaro for tirzepatide, or Wegovy vs Zepbound and Ozempic vs Wegovy for the semaglutide side. That keeps you on-label and gives you the best shot at coverage.

What Do Mounjaro and Ozempic Cost?

Separate list price, an eligible insurance copay, a manufacturer cash offer and a telehealth service fee. Your total depends on the prescribed product and plan. Our Ozempic savings guide and Mounjaro savings guide explain the branded routes before you compare other products.

If you're paying cash, telehealth companies advertise lower-priced compounded products, but they are not FDA-approved versions or generics of Mounjaro, Zepbound, Ozempic, or Wegovy:

• •Compounded tirzepatide microdose: Gala's current offer lists $149/mo on a three-month plan; confirm the selected medication and commitment at checkout. FDA has not reviewed this compounded product as identical or equivalent to Mounjaro or Zepbound.
• •Compounded tirzepatide AND semaglutide under one program: TrimRx advertises a $179 floor, but its terms list semaglutide at $199 first order/$299 follow-up and GLP-1 + GIP at $349 first order/$399 follow-up. Compounded only, no brand-name options; total under review.
• •Multiple compounded formats: SkinnyRx lists five compounded options, but FDA warning letter #717989 over its labeling and marketing is part of the record; the letter does not allege unsafe medication.
• •Lowest-cost featured pick: Embody, from $79/mo on a selected plan.
• •Compounded oral tirzepatide: Wellorithm’s oral dissolving tablets from $249/mo are not an approved tablet form of Mounjaro or Zepbound. Injection-trial outcomes do not establish their effectiveness.

To see every program ranked and priced, start with our best GLP-1 providers and the cheapest GLP-1 options. For the full pricing breakdown by drug, see the GLP-1 cost guide, tirzepatide cost, and the compounded tirzepatide guide. Run your specific numbers on the cost calculator.

How Do Their Side Effects Compare?

Both drugs share the GLP-1 side-effect profile, and the most common adverse events are gastrointestinal, nausea, diarrhea, vomiting, and constipation, concentrated during the dose-escalation phase. Slow, gradual dose increases are the main way doctors limit them.

The SURMOUNT-5 abstract reports that gastrointestinal effects were common in both groups, generally mild to moderate and most frequent during dose escalation. That was a weight-management trial without diabetes; it does not settle which diabetes medicine you personally would tolerate better.

Both carry a boxed warning for the risk of thyroid C-cell tumors based on rodent studies, and both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. For a practical playbook on managing day-to-day symptoms, see our GLP-1 side effects management guide.

Frequently Asked Questions

What Is the Next Useful Step?

Take the diabetes and weight-management evidence to your prescriber, then compare the product they consider appropriate. For weight management, read Wegovy versus Zepbound; for the ingredient and formulation differences, read semaglutide versus tirzepatide. If considering compounded cash-pay options, keep their approval status and product evidence separate from branded trial results.

Start with the best GLP-1 providers, find your lowest price on /cheapest, or take the 2-minute match quiz to see which program fits your situation.

Sources